$AARD

AstraZeneca (AZN) and Daiichi Sankyo (4568.T) won EU approval for Enhertu in breast cancer. Pfizer (PFE) expanded Talzenna-Xtandi use in prostate cancer. AbbVie (ABBV) got FDA approval for subcutaneous SKYRIZI in Crohn's disease. Artiva (ARTV) to cut 94% of workforce after halting AlloNK development. Tango (TNGX) plans 14% layoffs. Rakovina (RKV.V) and Celvion used AI to prioritize cancer types for ATR inhibitor. 60 Degrees (SXTP) partners for alpha-gal syndrome research.

Oppenheimer downgraded Aardvark Therapeutics (NASDAQ:AARD) to Perform, withdrawing its $21 price target. The stock fell 63% to $0.98, near its 52-week low, after mixed Phase 3 study results. The company plans to seek FDA feedback on a revised study design and resume clinical activities in 2027. H.C. Wainwright also lowered its price target to $2, citing ongoing challenges.

Analysts updated ratings and price targets for various U.S. companies. Notable changes include downgrades for 10x Genomics (TXG) and upgrades for Allegion (ALLE). Price targets were raised for AbbVie (ABBV), Amgen (AMGN), and others, while cuts were seen in sectors like retail and housing. Analysts favored growth and defensive sectors while showing caution toward consumer-sensitive areas.

H.C. Wainwright reduced its price target for Aardvark Therapeutics (NASDAQ:AARD) to $2 from $4, maintaining a Neutral rating. The stock fell 63% to $1.39. The FDA lifted a clinical hold on ARD-101 for Prader-Willi Syndrome, but the company faces cash burn and clinical trial delays.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials • HERO trial terminated early (67 of 90 planned participants randomized); all efficacy data are considered exploratory • HQ-CT scores fell by Week 2 of dose escala

Aardvark Therapeutics announced the FDA lifted its clinical hold on ARD-101 for treating hyperphagia in Prader-Willi Syndrome. The company plans to resume development after further FDA discussions and will host a webcast on October 23 to discuss trial data. A study found no cardiac events at tested doses.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data Clinical development of ARD-101 for hyperphagia in Prader-Willi Synd

H.C. Wainwright reduced its price target for Aardvark Therapeutics (NASDAQ:AARD) to $4.00 from $6.00, citing FDA's clinical hold on ARD-101 trials. The stock is down 15% in a week and 71% year-to-date. Aardvark is assessing unblinded data and discussing next steps with the FDA. The firm anticipates a delayed timeline for market entry.

U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche SAN